Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Tau local structure shields an amyloid-forming motif and controls aggregation propensity.

Chen D, Drombosky KW, Hou Z, Sari L, Kashmer OM, Ryder BD, Perez VA, Woodard DR, Lin MM, Diamond MI, Joachimiak LA.

Nat Commun. 2019 Jun 7;10(1):2493. doi: 10.1038/s41467-019-10355-1.

2.

Propagation of Protein Aggregation in Neurodegenerative Diseases.

Vaquer-Alicea J, Diamond MI.

Annu Rev Biochem. 2019 Jun 20;88:785-810. doi: 10.1146/annurev-biochem-061516-045049. Epub 2019 Mar 27.

PMID:
30917002
3.

Tau monomer encodes strains.

Sharma AM, Thomas TL, Woodard DR, Kashmer OM, Diamond MI.

Elife. 2018 Dec 11;7. pii: e37813. doi: 10.7554/eLife.37813.

4.

Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.

Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI.

J Biol Chem. 2019 Jan 18;294(3):1045-1058. doi: 10.1074/jbc.RA118.004471. Epub 2018 Nov 26.

5.

Rebuttal to Drs. Grinberg and Heinsen.

Kaufman SK, Del Tredici K, Braak H, Diamond MI.

Acta Neuropathol. 2018 Nov;136(5):819. doi: 10.1007/s00401-018-1917-9. Epub 2018 Oct 3. No abstract available.

PMID:
30284035
6.

Inert and seed-competent tau monomers suggest structural origins of aggregation.

Mirbaha H, Chen D, Morazova OA, Ruff KM, Sharma AM, Liu X, Goodarzi M, Pappu RV, Colby DW, Mirzaei H, Joachimiak LA, Diamond MI.

Elife. 2018 Jul 10;7. pii: e36584. doi: 10.7554/eLife.36584.

7.

Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART.

Kaufman SK, Del Tredici K, Thomas TL, Braak H, Diamond MI.

Acta Neuropathol. 2018 Jul;136(1):57-67. doi: 10.1007/s00401-018-1855-6. Epub 2018 May 11.

8.

Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates.

Stopschinski BE, Holmes BB, Miller GM, Manon VA, Vaquer-Alicea J, Prueitt WL, Hsieh-Wilson LC, Diamond MI.

J Biol Chem. 2018 Jul 6;293(27):10826-10840. doi: 10.1074/jbc.RA117.000378. Epub 2018 May 11.

9.

Profilin reduces aggregation and phase separation of huntingtin N-terminal fragments by preferentially binding to soluble monomers and oligomers.

Posey AE, Ruff KM, Harmon TS, Crick SL, Li A, Diamond MI, Pappu RV.

J Biol Chem. 2018 Mar 9;293(10):3734-3746. doi: 10.1074/jbc.RA117.000357. Epub 2018 Jan 22.

10.

The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition.

Eskandari-Sedighi G, Daude N, Gapeshina H, Sanders DW, Kamali-Jamil R, Yang J, Shi B, Wille H, Ghetti B, Diamond MI, Janus C, Westaway D.

Mol Neurodegener. 2017 Oct 4;12(1):72. doi: 10.1186/s13024-017-0215-7.

11.

Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue.

Kaufman SK, Thomas TL, Del Tredici K, Braak H, Diamond MI.

Acta Neuropathol Commun. 2017 Jun 7;5(1):41. doi: 10.1186/s40478-017-0442-8.

12.

Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid.

Saijo E, Ghetti B, Zanusso G, Oblak A, Furman JL, Diamond MI, Kraus A, Caughey B.

Acta Neuropathol. 2017 May;133(5):751-765. doi: 10.1007/s00401-017-1692-z. Epub 2017 Mar 14.

PMID:
28293793
13.

The prion model for progression and diversity of neurodegenerative diseases.

Stopschinski BE, Diamond MI.

Lancet Neurol. 2017 Apr;16(4):323-332. doi: 10.1016/S1474-4422(17)30037-6. Epub 2017 Feb 24. Review.

PMID:
28238712
14.

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.

DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA, Kordasiewicz HB, Swayze EE, Bennett CF, Diamond MI, Miller TM.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaag0481. doi: 10.1126/scitranslmed.aag0481.

15.

FRET and Flow Cytometry Assays to Measure Proteopathic Seeding Activity in Biological Samples.

Furman JL, Diamond MI.

Methods Mol Biol. 2017;1523:349-359.

PMID:
27975263
16.

Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo.

Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, Diamond MI.

Neuron. 2016 Nov 23;92(4):796-812. doi: 10.1016/j.neuron.2016.09.055. Epub 2016 Oct 27.

17.

Widespread tau seeding activity at early Braak stages.

Furman JL, Vaquer-Alicea J, White CL 3rd, Cairns NJ, Nelson PT, Diamond MI.

Acta Neuropathol. 2017 Jan;133(1):91-100. doi: 10.1007/s00401-016-1644-z. Epub 2016 Nov 22.

18.

Cellular Models for the Study of Prions.

Holmes BB, Diamond MI.

Cold Spring Harb Perspect Med. 2017 Feb 1;7(2). pii: a024026. doi: 10.1101/cshperspect.a024026. Review.

19.

Neuronal activity enhances tau propagation and tau pathology in vivo.

Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, Sanders DW, Cook C, Fu H, Boonen RA, Herman M, Nahmani E, Emrani S, Figueroa YH, Diamond MI, Clelland CL, Wray S, Duff KE.

Nat Neurosci. 2016 Aug;19(8):1085-92. doi: 10.1038/nn.4328. Epub 2016 Jun 20.

20.

Prions and Protein Assemblies that Convey Biological Information in Health and Disease.

Sanders DW, Kaufman SK, Holmes BB, Diamond MI.

Neuron. 2016 Feb 3;89(3):433-48. doi: 10.1016/j.neuron.2016.01.026. Review.

21.

Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry.

Furman JL, Holmes BB, Diamond MI.

J Vis Exp. 2015 Dec 8;(106):e53205. doi: 10.3791/53205.

22.

Photo-activatable Cre recombinase regulates gene expression in vivo.

Schindler SE, McCall JG, Yan P, Hyrc KL, Li M, Tucker CL, Lee JM, Bruchas MR, Diamond MI.

Sci Rep. 2015 Sep 9;5:13627. doi: 10.1038/srep13627.

23.

Propagation of prions causing synucleinopathies in cultured cells.

Woerman AL, Stöhr J, Aoyagi A, Rampersaud R, Krejciova Z, Watts JC, Ohyama T, Patel S, Widjaja K, Oehler A, Sanders DW, Diamond MI, Seeley WW, Middleton LT, Gentleman SM, Mordes DA, Südhof TC, Giles K, Prusiner SB.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4949-58. doi: 10.1073/pnas.1513426112. Epub 2015 Aug 18.

24.

Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.

Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI.

J Biol Chem. 2015 Aug 28;290(35):21652-62. doi: 10.1074/jbc.M115.657924. Epub 2015 Jun 30.

25.

Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation.

Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI.

J Biol Chem. 2015 Jun 12;290(24):14893-903. doi: 10.1074/jbc.M115.652693. Epub 2015 Apr 17.

26.

Anti-tau antibody reduces insoluble tau and decreases brain atrophy.

Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM.

Ann Clin Transl Neurol. 2015 Mar;2(3):278-88. doi: 10.1002/acn3.176. Epub 2015 Jan 23.

27.

Subcellular localization and Ser-137 phosphorylation regulate tumor-suppressive activity of profilin-1.

Diamond MI, Cai S, Boudreau A, Carey CJ Jr, Lyle N, Pappu RV, Swamidass SJ, Bissell M, Piwnica-Worms H, Shao J.

J Biol Chem. 2015 Apr 3;290(14):9075-86. doi: 10.1074/jbc.M114.619874. Epub 2015 Feb 13.

28.

The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios.

Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J.

FEBS Lett. 2015 Jan 2;589(1):77-83. doi: 10.1016/j.febslet.2014.11.026. Epub 2014 Nov 29.

29.

Proteopathic tau seeding predicts tauopathy in vivo.

Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4376-85. doi: 10.1073/pnas.1411649111. Epub 2014 Sep 26.

30.

Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target.

Holmes BB, Diamond MI.

J Biol Chem. 2014 Jul 18;289(29):19855-61. doi: 10.1074/jbc.R114.549295. Epub 2014 May 23. Review.

31.

Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI.

Neuron. 2014 Jun 18;82(6):1271-88. doi: 10.1016/j.neuron.2014.04.047. Epub 2014 May 22.

32.

Advances in diagnostic testing for Alzheimer disease.

Schindler SE, McConathy J, Ances BM, Diamond MI.

Mo Med. 2013 Sep-Oct;110(5):401-5. Review.

33.

Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM.

Neuron. 2013 Oct 16;80(2):402-414. doi: 10.1016/j.neuron.2013.07.046. Epub 2013 Sep 26.

34.

Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones.

Udan-Johns M, Bengoechea R, Bell S, Shao J, Diamond MI, True HL, Weihl CC, Baloh RH.

Hum Mol Genet. 2014 Jan 1;23(1):157-70. doi: 10.1093/hmg/ddt408. Epub 2013 Aug 19.

35.

Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.

Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47. doi: 10.1073/pnas.1301440110. Epub 2013 Jul 29.

36.

Prion-like propagation of protein aggregation and related therapeutic strategies.

Kaufman SK, Diamond MI.

Neurotherapeutics. 2013 Jul;10(3):371-82. doi: 10.1007/s13311-013-0196-3. Review.

37.

A strong consensus has emerged around the role of protein misfolding and aggregation in the pathogenesis of neurodegeneration. Introduction.

Diamond MI.

Neurotherapeutics. 2013 Jul;10(3):369-70. doi: 10.1007/s13311-013-0197-2. No abstract available.

38.

Mechanisms of protein seeding in neurodegenerative diseases.

Walker LC, Diamond MI, Duff KE, Hyman BT.

JAMA Neurol. 2013 Mar 1;70(3):304-10. Review.

39.

Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease.

Li M, Yasumura D, Ma AA, Matthes MT, Yang H, Nielson G, Huang Y, Szoka FC, Lavail MM, Diamond MI.

PLoS One. 2013;8(2):e56026. doi: 10.1371/journal.pone.0056026. Epub 2013 Feb 11.

40.

An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1.

Zheng Z, Li A, Holmes BB, Marasa JC, Diamond MI.

J Biol Chem. 2013 Mar 1;288(9):6063-71. doi: 10.1074/jbc.M112.413575. Epub 2013 Jan 14.

41.

Amyotrophic lateral sclerosis and organ donation: is there risk of disease transmission?

Holmes BB, Diamond MI.

Ann Neurol. 2012 Dec;72(6):832-6. doi: 10.1002/ana.23684. Review.

42.

Cellular mechanisms of protein aggregate propagation.

Holmes BB, Diamond MI.

Curr Opin Neurol. 2012 Dec;25(6):721-6. doi: 10.1097/WCO.0b013e32835a3ee0. Review.

43.

Huntington disease and the huntingtin protein.

Zheng Z, Diamond MI.

Prog Mol Biol Transl Sci. 2012;107:189-214. doi: 10.1016/B978-0-12-385883-2.00010-2. Review.

PMID:
22482451
44.

Protein phosphatase 1 dephosphorylates profilin-1 at Ser-137.

Shao J, Diamond MI.

PLoS One. 2012;7(3):e32802. doi: 10.1371/journal.pone.0032802. Epub 2012 Mar 30.

45.

Trans-cellular propagation of Tau aggregation by fibrillar species.

Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI.

J Biol Chem. 2012 Jun 1;287(23):19440-51. doi: 10.1074/jbc.M112.346072. Epub 2012 Mar 29.

46.

An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Fuentealba RA, Marasa J, Diamond MI, Piwnica-Worms D, Weihl CC.

Hum Mol Genet. 2012 Feb 1;21(3):664-80. doi: 10.1093/hmg/ddr500. Epub 2011 Nov 3.

47.

In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.

Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM.

J Neurosci. 2011 Sep 14;31(37):13110-7. doi: 10.1523/JNEUROSCI.2569-11.2011.

48.

Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43.

Fuentealba RA, Udan M, Bell S, Wegorzewska I, Shao J, Diamond MI, Weihl CC, Baloh RH.

J Biol Chem. 2010 Aug 20;285(34):26304-14. doi: 10.1074/jbc.M110.125039. Epub 2010 Jun 16.

49.

F-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristics.

Angeli S, Shao J, Diamond MI.

PLoS One. 2010 Feb 4;5(2):e9053. doi: 10.1371/journal.pone.0009053.

50.

Prion-like mechanisms in neurodegenerative diseases.

Frost B, Diamond MI.

Nat Rev Neurosci. 2010 Mar;11(3):155-9. doi: 10.1038/nrn2786. Epub 2009 Dec 23. Review.

Supplemental Content

Loading ...
Support Center